Compare ECVT & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECVT | WGS |
|---|---|---|
| Founded | 1935 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2017 | 2020 |
| Metric | ECVT | WGS |
|---|---|---|
| Price | $10.39 | $77.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $14.00 | ★ $120.71 |
| AVG Volume (30 Days) | ★ 1.2M | 790.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $723,515,000.00 | $427,539,000.00 |
| Revenue This Year | $29.07 | $29.98 |
| Revenue Next Year | $6.71 | $25.92 |
| P/E Ratio | $94.45 | ★ N/A |
| Revenue Growth | 2.70 | ★ 39.97 |
| 52 Week Low | $7.41 | $32.21 |
| 52 Week High | $15.09 | $170.87 |
| Indicator | ECVT | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 63.03 |
| Support Level | $9.67 | $56.36 |
| Resistance Level | $11.31 | $96.34 |
| Average True Range (ATR) | 0.40 | 5.73 |
| MACD | -0.13 | 0.94 |
| Stochastic Oscillator | 14.52 | 77.27 |
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.